# Formula N-111: Advanced Cognitive Enhancement & Neuroprotection

**PHYSICIAN USE ONLY | RESEARCH PEPTIDES**

*Last Updated: February 5, 2026*

---

## 1. Composition & Overview

**Formula Classification:** Multi-pathway neuro-regenerative and nootropic protocol – enteric-coated research capsule designed for physician-directed use only.

**Per Capsule Composition:**
- J147 – 10 mg
- Dihexa – 10 mg
- Noopept – 10 mg

**Delivery System:**
- Enteric-coated oral capsule for daily use, designed to protect the components from gastric degradation and ensure optimal absorption and blood-brain barrier penetration.

**Therapeutic Intent:**
- To provide a comprehensive, multi-layered approach to cognitive enhancement and neuroprotection by simultaneously targeting cellular energy (mitochondria), neural structure (synaptogenesis), and neurochemical signaling (neurotransmitter modulation). This formula is designed for both immediate cognitive enhancement and long-term structural brain health.

---

## 2. Detailed Mechanism of Action

Formula N-111 integrates three powerful nootropic agents that work in concert to optimize brain function from the ground up.

### 2.1 J147: Mitochondrial & Metabolic Optimization

J147 is a novel neurotrophic compound that targets the mitochondrial ATP synthase, the engine of cellular energy production [1]. By modulating its activity, J147 increases ATP levels, reduces oxidative stress, and activates the AMPK longevity pathway, creating a healthier and more resilient neuronal environment [2, 3].

### 2.2 Dihexa: Structural Synaptogenesis

Dihexa is a potent angiotensin IV analog that activates the HGF/c-Met system, a key pathway for neuronal growth and repair. It is a powerful synaptogenic agent, promoting the formation of new synapses and increasing dendritic spine density, which is the structural basis of learning and memory [4, 5].

### 2.3 Noopept: Neurotransmitter & Neurotrophin Modulation

Noopept is a fast-acting dipeptide that enhances cognitive function by modulating AMPA and NMDA glutamate receptors, facilitating long-term potentiation (LTP). It also increases the expression of NGF and BDNF, key neurotrophic factors for neuronal survival and plasticity [6, 7].

---

## 3. Synergistic Integration Table

| Level | Primary Pathway | Key Components | Integrated Clinical Effect |
|---|---|---|---|
| Foundational | Mitochondrial & Metabolic Health | J147 | Enhanced cellular energy, reduced oxidative stress, and a pro-longevity environment for neurons. |
| Structural | Synaptogenesis & Neural Architecture | Dihexa | Building of new neural connections and increased synaptic density, the physical substrate of memory. |
| Functional | Neurotransmission & Plasticity | Noopept | Enhanced speed and efficiency of signal transmission across neural networks, facilitating learning and recall. |

---

## 4. Key Clinical Benefits

| Domain | Key Benefits |
|---|---|
| Memory & Learning | Enhanced memory formation, consolidation, and rapid recall; improved learning capacity and speed. |
| Cognitive Function | Increased mental clarity, focus, and processing speed; improved executive function and problem-solving skills. |
| Neuroprotection | Robust, multi-pathway protection against age-related cognitive decline, oxidative stress, and neuroinflammation. |
| Mood & Resilience | Improved mood stability, reduced anxiety, and enhanced resilience to stress. |

---

## 5. Patient Expectations & Timeline

| Timeframe | Expected Changes |
|---|---|
| 1-3 Days | Initial increase in mental clarity, focus, and verbal fluency from Noopept. |
| 1-2 Weeks | More consistent cognitive enhancement; noticeable improvements in memory recall and learning speed. |
| 1-3 Months | Significant improvements in overall cognitive function; enhanced problem-solving abilities and creative thought. Structural brain changes are occurring. |
| 3-6+ Months | Long-term consolidation of cognitive gains; sustained neuroprotection and enhanced brain health. |

---

## 6. Dosing & Administration

- **Standard Dose:** One capsule daily, typically in the morning.
- **Timing:** Consistent daily use is essential for long-term structural benefits.
- **Optimization:** Can be cycled (e.g., 5 days on, 2 days off) to maintain sensitivity, though continuous use is generally recommended.

---

## 7. Safety Profile

- **Overall:** All three components have favorable safety profiles in preclinical studies. J147 has passed Phase 1 human trials. Noopept has a long history of clinical use.
- **Absolute Contraindications:** Pregnancy and lactation; known hypersensitivity.
- **Relative Cautions:** Use with caution in patients with a history of seizures (theoretical risk with AMPA modulation).
- **Tolerability:** Generally well-tolerated. Some users report mild, transient headache or irritability with Noopept, which often resolves with dose adjustment or co-administration with a choline source.

---

## 8. Drug Interaction Considerations

| Drug/Class | Interaction / Management |
|---|---|
| Stimulants (e.g., Amphetamine) | Potential for additive effects; use with caution. |
| Anticonvulsants | May alter seizure threshold; consult with a physician. |

---

## 9. References

[1] Goldberg, J., et al. (2018). The mitochondrial ATP synthase is a shared drug target for aging and dementia. *Aging Cell*, 17(2), e12715.

[2] Larrick, J. W., & Mendelsohn, A. R. (2018). ATP Synthase, a Target for Dementia and Aging? *Rejuvenation Research*, 21(2), 168-172.

[3] Prior, M., et al. (2013). The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice. *Alzheimer's Research & Therapy*, 5(3), 25.

[4] Sun, X., et al. (2021). AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway. *Brain Sciences*, 11(11), 1487.

[5] Wright, J. W., & Harding, J. W. (2019). Contributions by the Brain Renin-Angiotensin System to Memory, Cognition, and Alzheimer's Disease. *Journal of Alzheimer's Disease*, 67(2), 469-482.

[6] Kondratenko, R. V., et al. (2022). Effect of nootropic dipeptide noopept on CA1 pyramidal neurons involves α7AChRs on interneurons in hippocampal slices from rat. *Neuroscience Letters*, 789, 136884.

[7] Ostrovskaya, R. U., et al. (2008). Noopept stimulates the expression of NGF and BDNF in rat hippocampus. *Bulletin of Experimental Biology and Medicine*, 146(3), 334-337.
